CCN2 and breast carcinoma: The combination of trastuzumab (an mAB targeting human epidermal growth factor receptor 2 in breast cancer) and hyaluronidase‐osyk, commercially available as Herceptin Hylecta, has shown that the use of the latter facilitates the subcutaneous dispersion of the antibody by inducing hyaluronan degradation.[8] Moreover, Pamrevlumab, a commercially available mAB against connective tissue growth factor (CTGF), is currently under Phase 3 study as a neoadjuvant for chemotherapy in pancreatic cancer (NCT03941093).